These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33048862)

  • 1. Fezolinetant findings can fuel future instrumentation inquiries.
    Carpenter JS
    Menopause; 2020 Dec; 27(12):1347. PubMed ID: 33048862
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
    Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.
    Douxfils J; Beaudart C; Dogné JM
    Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107
    [No Abstract]   [Full Text] [Related]  

  • 5. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
    Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
    Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
    Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
    [No Abstract]   [Full Text] [Related]  

  • 7. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes.
    Reame NK
    Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443
    [No Abstract]   [Full Text] [Related]  

  • 8. Fezolinetant: First Approval.
    Lee A
    Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact.
    Yamamoto K; Inuki S; Ohno H; Oishi S
    Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
    Gompel A; Stuenkel CA
    Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition.
    Cully M
    Nat Rev Drug Discov; 2017 May; 16(6):377. PubMed ID: 28559557
    [No Abstract]   [Full Text] [Related]  

  • 12. Fezolinetant.
    Am J Health Syst Pharm; 2023 Aug; 80(17):1113-1114. PubMed ID: 37382493
    [No Abstract]   [Full Text] [Related]  

  • 13. Fezolinetant.
    Beninger P
    Clin Ther; 2023 Aug; 45(8):802-803. PubMed ID: 37442655
    [No Abstract]   [Full Text] [Related]  

  • 14. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
    Crespo C; Erlich D
    Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
    [No Abstract]   [Full Text] [Related]  

  • 15. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
    Reed SD
    Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
    [No Abstract]   [Full Text] [Related]  

  • 16. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
    Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
    [No Abstract]   [Full Text] [Related]  

  • 17. Totality of evidence refutes neoplasm risk with fezolinetant.
    Neal-Perry G; Santoro N; Cano A; Nappi RE; Shapiro M; Ottery FD
    Lancet; 2024 May; 403(10440):1987-1988. PubMed ID: 38762322
    [No Abstract]   [Full Text] [Related]  

  • 18. Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.
    Douxfils J; Beaudart C; Dogné JM
    Lancet; 2024 May; 403(10440):1988. PubMed ID: 38762323
    [No Abstract]   [Full Text] [Related]  

  • 19. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
    Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
    J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.
    Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):748-756. PubMed ID: 28802064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.